Trial Profile

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Registrational
Acronyms ASSURE
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

15 Jun 2023 Results (n=17) assessing whether treatment with the BTK inhibitor acalabrutinib improves innate immune responses and restores immune dysfunction in patients with CLL presented at the 28th Congress of the European Haematology Association
02 Dec 2021 Status changed from recruiting to active, no longer recruiting.
12 Nov 2020 Eligibility criteria amended to include subjects from 18 years to 130 years.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com